All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Treatment sequencing for anemic myelofibrosis

with Jean-Jacques Kiladjian & Angela Fleischman

Monday, February 26, 2024 | 16:30 CET

This independent educational activity is supported by Bristol Myers Squibb. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.


The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

What is the use for monoclonal antibodies in MPN?

Nov 14, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in myeloproliferative neoplasms.

Bookmark this article

During the 14th International Congress of Myeloproliferative Neoplasms, the MPN Hub was pleased to speak to Ann Mullally, Brigham and Women's Hospital, Boston, US. We asked, What is the use for monoclonal antibodies in myeloproliferative neoplasms (MPN)?

What is the use for monoclonal antibodies in MPN?

Mullally begins by summarizing preclinical studies on mutant calreticulin (CALR) as a target for monoclonal antibody (mAb) treatment in MPN. The unique altered sequence on mutant CALR makes it an ideal target for a mAb as unwanted effects on normal cells can be avoided. Mullally concludes by highlighting an oral communication in the upcoming 64th American Society Hematology Annual Meeting and Exposition, where we are going to learn more about the impact of these novel anti-mutant CALR mAbs on platelet count and cell growth in a mouse model.


Subscribe to get the best content related to MPN delivered to your inbox